仑伐替尼联合TACE辅助治疗术后高复发风险肝细胞癌患者:LANCE研究结果更新  

Adjuvant Lenvatinib in Combination With TACE for HCC Patients With High Risk of Postoperative Relapse:Updated of LANCE Study

作　　者：张必翔[1] 邹威 ZHANG Bi-xiang;ZOU Wei(Department of Surgery,Hepatic Surgery Center,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;不详)

机构地区：[1]华中科技大学同济医学院附属同济医院肝脏外科中心,武汉430030 [2]广东省人民医院综合(介入)肿瘤一科,广州510080

出　　处：《循证医学》2021年第6期329-331,共3页The Journal of Evidence-Based Medicine

摘　　要：1文献来源Chen J,Lu L,Wen T,et al. 2021 ESMO 945P-Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE):Updated results from a multi-center prospective cohort study[J]. Ann Oncol,2021,32(5S):S818-S828.

关 键 词：肝细胞癌 仑伐替尼 肝动脉化疗栓塞 

分 类 号：R735.7[医药卫生—肿瘤]